Losatuxizumab (ABT-806) is an anti-EGFR monoclonal antibody. Losatuxizumab binds to EGFR with EC50s of 0.96 nM for EGFR wild-type, 0.09 nM for EGFRC271A,C283A, 0.12 nM for EGFRvIII, 0.66 nM for EGFR1-501. Losatuxizumab can be used for research of EGFR-expressing cancers.
Losatuxizumab (0.001 nM-100 nM) binds to EGFRvIII-expressing cell line U87MGde2-7[1].Losatuxizumab inhibits EGF-mediated EGFR phosphorylation in a NR6 huEGFRC271A,C283A cell line, with an IC50 of 1.2 nM[2].
Lorigerlimab has antitumor activities in various wild-type EGFR-expressing squamous cell carcinoma xenograft model[1].Lorigerlimab (40 mg/kg, i.p.) significantly inhibits growth of U87MGde2-7 tumor in mice[1].Lorigerlimab (10 and 40 mg/kg, i.p.) prolongs survival and reduces levels of pEGFR in PDX GBM model (SN0207 tumor)[1].
References:
[1]. Reilly EB, et al. Characterization of ABT-806, a Humanized Tumor-Specific Anti-EGFR Monoclonal Antibody. Mol Cancer Ther. 2015 May;14(5):1141-51.
[2]. Phillips AC, et al. ABT-414, an Antibody-Drug Conjugate Targeting a Tumor-Selective EGFR Epitope. Mol Cancer Ther. 2016 Apr;15(4):661-9.